Shares of Cybin Inc. (OTCMKTS:CYBN – Get Free Report) were up 1.8% during trading on Thursday . The company traded as high as $10.40 and last traded at $10.19. Approximately 266,856 shares were traded during mid-day trading, an increase of 32% from the average daily volume of 201,422 shares. The stock had previously closed at $10.01.
Cybin Price Performance
The firm has a market capitalization of $200.52 million, a price-to-earnings ratio of -52.79 and a beta of 0.44. The business has a fifty day moving average price of $9.82 and a two-hundred day moving average price of $6.46.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Stories
- Five stocks we like better than Cybin
- Pros And Cons Of Monthly Dividend Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
- How to Calculate Inflation Rate
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Where to Find Earnings Call Transcripts
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
